PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 31, 2026Clinical Therapeutics0 citations

Response to Letter to the Editor: Commending the Feasibility of CYP2C19 Pharmacogenetic Testing in Personalized Antiplatelet Therapy—Insights and Perspectives

View Full Paper
RARania Abdel-LatifWMWadha Al MuftahSMShaban Mohammed

Key Points

Key points are not available for this paper at this time.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Abdel-Latif et al. (2026) studied this question.

synapsesocial.com/papers/6a025c98edf6f481385947c8https://doi.org/10.1016/j.clinthera.2026.02.002
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Pharmacogenetics: From Bench to Byte— An Update of Guidelines2011 · 1,020 citations
  2. 2Short- and long-term cost-effectiveness analysis of CYP2C19 genotype-guided therapy, universal clopidogrel, versus universal ticagrelor in post-percutaneous coronary intervention patients in Qatar2021 · 16 citations
  3. 3Letter to the Editor: Commending the Feasibility of CYP2C19 Pharmacogenetic Testing in Personalized Antiplatelet Therapy—Insights and Perspectives2026 · 1 citations
  4. 4Evaluating the public health impact of health promotion interventions: the RE-AIM framework.1999 · 7,526 citations
  5. 5Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update2022 · 506 citations